Status:
COMPLETED
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborating Sponsors:
Pfizer
Conditions:
Atopic Dermatitis
Eczema
Eligibility:
All Genders
4-17 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to develop biomarkers to predict what medication is best for each child with atopic dermatitis (eczema). Participants will come in to Lurie Children's Allergy of Dermatolo...
Detailed Description
The overall study design is an intervention open-label non-randomized clinical trial of Eucrisa treatment (Eucrisa is an FDA approved drug for this indication and in this age group) twice daily for 28...
Eligibility Criteria
Inclusion
- AD diagnosis by dermatologist or allergist based on Hanifin and Rajka criteria
- 5% or more treatable body surface area involvement
- baseline Investigator's Static Assessment (ISGA) score of mild (2) or moderate (3)
- patient on stable regimens (consistent use 14 days before day 1 of enrollment) of inhaled corticosteroids and antihistamines
- must have lesional skin in the antecubital fossa
Exclusion
- use of topical corticosteroid, calcineurin inhibitor, or PDE4 inhibitor within 14 days of enrollment
- significant active infection
- any previous use of biologic therapy
- no pruritus at baseline visit, or other pruritic condition
- washing/moisturizer use 24 hours prior to tape strip biomarker collection at site
- uncontrolled asthma, uncontrolled allergic rhinitis, or other sleep disturbing condition
Key Trial Info
Start Date :
October 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04023084
Start Date
October 3 2019
End Date
February 11 2022
Last Update
July 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611